In recent years, the escalating prevalence of opioid use during pregnancy has precipitated a troubling rise in prenatal opioid exposure (POE) and consequently, neonatal opioid withdrawal syndrome (NOWS). This phenomenon is emerging as a critical public health issue given its far-reaching implications on the developing brain. Despite the growing incidence rates, our understanding of the long-term neurodevelopmental outcomes stemming from prenatal opioid exposure remains fragmented and underexplored. This gap in knowledge prompted an extensive systematic review that synthesized evidence spanning human and animal research, offering unprecedented insights into the complex neurobiological and behavioral sequelae of POE and NOWS.

The systematic analysis capitalized on vast databases including PubMed, Embase, CINAHL, APA, and PsycINFO, harvesting 14 pertinent studies published over two decades, from 2000 to 2021. These studies encompassed 12 investigations in human populations and 2 experimental models in animals, highlighting both clinical observations and controlled mechanistic explorations. Due to the heterogeneity of study designs, participant demographics, and outcome measures, traditional meta-analytic techniques were eschewed in favor of a narrative synthesis approach known as Synthesis Without Meta-analysis (SWiM). This methodology allowed for a cohesive integration of disparate data, elucidating patterns that might otherwise be obscured.

Among human studies, the evidence consistently details a constellation of developmental challenges in children exposed prenatally to opioids. These challenges encompass deficits across multiple domains including cognitive function, language acquisition, and motor skills. More alarmingly, POE is linked to a heightened risk of neurobehavioral disorders such as attention deficit hyperactivity disorder (ADHD) and broader behavioral dysregulation manifesting through childhood and adolescence. Academic underachievement also emerges as a significant correlate, suggesting that the repercussions of POE extend beyond early infancy and permeate into formative educational years, potentially impairing life trajectory.

Complementing behavioral assessments, neuroimaging findings from the reviewed human studies reveal substantive structural brain alterations associated with POE. Notably, disruptions in white matter integrity have been identified, implicating compromised neural connectivity as a likely substrate underpinning observed cognitive and behavioral deficits. White matter, critical for efficient communication between disparate brain regions, appears particularly vulnerable to in utero opioid exposure. Such structural perturbations portend enduring effects on functional brain networks that govern attention, executive function, and emotional regulation.

Animal models augment these human data by enabling controlled investigations of neurobiological mechanisms underlying POE-induced deficits. Studies employing rodent paradigms have documented phenotypes including hyperactivity, impaired motor coordination, and reduced cortical neuronal density. These findings suggest that opioid exposure during critical windows of neurodevelopment interferes with neuronal proliferation, differentiation, or survival. Altered physiological markers also accompany behavioral impairments, hinting at dysregulation of neurochemical systems and neuroimmune interactions that may exacerbate developmental vulnerabilities.

The combined human and animal literature converges on a disconcerting narrative: prenatal opioid exposure that results in neonatal withdrawal exerts deleterious effects on brain maturation with potentially lifelong consequences. This underscores the notion that NOWS constitutes more than an acute neonatal condition; it sets in motion complex developmental cascades that may shape neurocognitive and behavioral trajectories well beyond the neonatal period. Such insight reframes clinical approaches, advocating for early detection and sustained intervention strategies to mitigate long-term adverse outcomes.

Given the multisystemic nature of opioid action, it is plausible that POE disrupts myriad neurodevelopmental processes. Opioids bind to mu-opioid receptors abundantly expressed in fetal brain regions integral to neurogenesis and synaptogenesis. Perturbations in these signaling pathways during gestation could disrupt neuronal circuitry assembly, myelination, and neurotransmitter system maturation. Additionally, prenatal opioid exposure may provoke inflammatory responses or oxidative stress, further compounding neural injury and functional impairment.

The heterogeneity in study designs and outcome measures across the existing literature highlights the pressing need for standardized, longitudinal research frameworks. Prospective cohort studies with comprehensive neurodevelopmental assessments and multimodal neuroimaging are essential to delineate the temporal progression of deficits and identify potential recovery windows. Moreover, elucidating potential moderating factors such as genetic susceptibility, polysubstance exposure, postnatal environment, and early therapeutic interventions will advance precision medicine approaches for affected populations.

In light of these findings, healthcare providers must adopt an integrative lens when managing pregnant women with opioid use disorder and their offspring. Strategies extending beyond neonatal abstinence syndrome management to encompass developmental surveillance and early childhood intervention programs are critical. Tailored support services including cognitive-behavioral therapies, educational assistance, and family support can substantially improve outcomes. Advocating for such comprehensive care models within public health frameworks remains paramount.

Furthermore, public policy initiatives should prioritize prevention of opioid misuse during pregnancy through enhanced access to medication-assisted treatments and psychosocial support. Raising awareness about the profound neurodevelopmental implications of prenatal opioid exposure among patients, clinicians, and policymakers can galvanize concerted efforts to curtail this emerging epidemic. Investment in research exploring safe, effective treatment modalities during pregnancy will also be instrumental in mitigating POE-related harms.

Technology-enabled prenatal screening tools and biomarkers for risk stratification offer promising avenues for early identification of infants at highest risk for adverse outcomes. Coupling these diagnostic advances with interdisciplinary clinical teams including neonatologists, neurologists, developmental pediatricians, and mental health specialists will optimize care pathways. Ensuring culturally sensitive, equitable access to such specialized services is essential to address disparities often observed in populations disproportionately affected by opioid use.

The urgency of this public health challenge is underscored by the generational repercussions that compromised neurodevelopment may engender. Impaired cognitive and behavioral functioning in children with POE and NOWS not only diminishes quality of life but also engenders socioeconomic burdens through increased healthcare utilization, educational support needs, and potential involvement with juvenile justice systems. Proactive, evidence-based strategies to intercept these trajectories thus carry profound societal import.

In summary, the expanding body of research synthesized in this comprehensive review illuminates the detrimental impact of prenatal opioid exposure on child brain development and behavior, with neonatal opioid withdrawal syndrome serving as a critical phenotypic marker of such exposure. These insights mandate a paradigm shift toward multifaceted, sustained interventions that address both biomedical and psychosocial determinants of health from birth through adolescence. Bridging current knowledge gaps through rigorous study designs and translational research remains an imperative to improve outcomes for vulnerable infants and families affected by the ongoing opioid crisis.

The path forward demands collaborative engagement among clinicians, researchers, public health officials, and communities to mitigate the neurodevelopmental toll of the opioid epidemic. Harnessing cutting-edge neurotechnologies and harnessing the potential for neuroplasticity during early childhood may offer hope for meaningful remediation. As society grapples with the evolving dimensions of this crisis, safeguarding the developing brains of future generations emerges as an ethical and scientific priority of paramount importance.

Subject of Research:

Article Title:

Article References:
Rajaprakash, M., West, S., Jayakumar, S. et al. Neurodevelopmental outcomes of prenatal opioid exposure and neonatal opioid withdrawal syndrome: A systematic review from birth to early adulthood. J Perinatol (2025). https://doi.org/10.1038/s41372-025-02496-7

Image Credits: AI Generated

DOI: 15 December 2025

Keywords: prenatal opioid exposure, neonatal opioid withdrawal syndrome, neurodevelopment, cognitive impairment, white matter disruption, ADHD, behavioral disorders, neuroimaging, animal models, neuroplasticity

In recent years, the potential risks of opioid use during pregnancy have increasingly come under scientific scrutiny, especially concerns revolving around possible neurodevelopmental consequences for children. Opioid pain medications are commonly prescribed to pregnant individuals to alleviate various painful conditions, but their safety profiles regarding fetal brain development remain incompletely understood. A groundbreaking study led by Emma N. Cleary of Indiana University Bloomington now provides compelling evidence that questions the previously suggested direct link between prescribed opioid analgesics taken during pregnancy and elevated risks of autism spectrum disorder (ASD) and attention-deficit/hyperactivity disorder (ADHD) in offspring.

Opioids represent a class of powerful analgesics that act primarily on the central nervous system. Their utility in managing moderate to severe pain has led to their widespread use, including among pregnant individuals. However, the developing fetal brain is known to be sensitive to environmental exposures, and certain drugs may carry risks of neurodevelopmental disturbances. ASD and ADHD are complex neurodevelopmental disorders characterized by difficulties in social communication, behavior regulation, and attention control. Past epidemiological studies have hinted at increased incidences of these disorders among children prenatally exposed to opioids, creating concern among health professionals and expectant parents alike.

The recent investigation, published in the open-access journal PLOS Medicine, capitalized on Sweden’s comprehensive national health registers to analyze an unprecedentedly large sample size. The research analyzed over 1.2 million children born between 2007 and 2018 to assess ASD outcomes, alongside more than 900,000 children born between 2007 and 2015 to track ADHD diagnoses. Crucially, the study cross-referenced these health outcomes with detailed prescription records of opioid analgesics used by the mothers during pregnancy, enabling a nuanced analysis of dosage, duration, and timing of exposure.

Initial observations found that children with prenatal opioid exposure had a higher raw incidence of ASD and ADHD diagnoses compared to their unexposed counterparts. Specifically, 2.0% of children without prenatal opioid exposure were diagnosed with ASD by age ten, while rates rose to 2.9% and 3.6% among children exposed to low and high opioid doses, respectively. Similar upward gradients appeared for ADHD prevalence, lending initial support to concerns about opioid-related neurodevelopmental risks. However, these raw figures alone cannot establish causation due to potential confounding variables that may influence both opioid use during pregnancy and neurodevelopmental outcomes.

To address these complexities, Cleary and colleagues employed sophisticated statistical methods to disentangle the direct effects of opioid exposure from confounding genetic and environmental factors. They included sibling comparison analyses, which control for shared familial and genetic influences by comparing outcomes among siblings discordant for opioid exposure in utero. Such methodological rigor is essential to mitigate bias from unmeasured confounders that might otherwise create spurious associations. These approaches revealed that when family-related confounds were accounted for, the elevated risks of ASD and ADHD linked to opioid exposure diminished substantially, in some analyses disappearing entirely.

One significant limitation recognized by the authors involves the range of opioid exposures captured within Swedish prescription data. Extremely high doses or prolonged opioid use were rare due to regulatory and clinical prescribing patterns in Sweden, narrowing the applicability of the conclusions to typical or low-to-moderate exposure levels. Therefore, the study refrains from implying safety at very high opioid dosages or for extended treatment durations. Nonetheless, for the bulk of opioid prescriptions seen in this population, the findings argue against a causal relationship with increased ASD or ADHD risk.

Beyond the epidemiological findings, this research has important clinical ramifications. Pregnant individuals needing pain management encounter a dilemma: untreated pain may have adverse maternal and fetal consequences, yet potential risks of pharmacological interventions weigh heavily on decision-making. Providing clearer evidence that prescribed opioids, within typical dosage ranges, do not markedly elevate neurodevelopmental disorder risks allows healthcare providers and patients to better weigh benefits and harms. Emma N. Cleary highlights that while small risks at high exposures cannot be fully excluded, the bulk of evidence suggests no direct causal link, thus informing safer clinical pain management during pregnancy.

Co-author Ayesha C. Sujan emphasizes that the findings underscore the importance of considering upstream factors that lead to opioid use, rather than solely the pharmacological effects of opioids themselves. Conditions precipitating opioid prescriptions, such as chronic pain, mental health disorders, or socioeconomic stressors, may themselves be associated with neurodevelopmental risks. This insight calls for a holistic approach to supporting pregnant individuals who experience pain, advocating for psychosocial support and alternative evidence-based pain management strategies that integrate both pharmaceutical and non-pharmaceutical options.

The study’s scope, leveraging vast national registers and employing robust analytical frameworks, represents an archetype for future research dissecting prenatal risk factors for neurodevelopmental disorders. It demonstrates how large-scale observational data, when properly controlled for confounding, can clarify complex exposure-outcome relationships that randomized controlled trials are impractical or unethical to address. Furthermore, the multinational collaboration involving researchers from the United States, Sweden, and the United Kingdom exemplifies the value of cross-disciplinary and international partnerships in tackling pressing public health questions.

In the context of the ongoing opioid epidemic and the critical need for safe pain management practices, this research reassures that prescribed opioid analgesics, as administered in routine clinical practice during pregnancy in Sweden, do not independently drive increased risks of ASD or ADHD in children. It also advocates for nuanced interpretation of risks associated with prenatal medication exposure, avoiding unnecessary alarm while not dismissing the importance of appropriate scrutiny and caution.

Future studies would benefit from extending investigations to populations with variable opioid prescribing practices, and from integrating biological markers of exposure and genetic susceptibility. Understanding potential gene-environment interactions could further illuminate individual-level vulnerabilities or resilience to opioid-related effects on neurodevelopment. The balance between effective maternal pain control and fetal safety remains delicate, yet this new evidence brings greater clarity to one aspect of this complex equation.

As the research community continues to unravel the intricate pathways influencing neurodevelopmental outcomes, robust evidence such as this will assist clinicians, policymakers, and expectant families in making informed decisions. The recognition that observed associations between prenatal opioid exposure and ASD or ADHD risk may largely be artifacts of confounding highlights the essential role of rigorous epidemiological methodologies in public health science.

Emma N. Cleary and colleagues have thus contributed a pivotal piece to the puzzle of prenatal opioid safety, hopeful that their findings will reduce anxiety and stigma around opioid use in pregnancy when appropriately prescribed, while encouraging comprehensive care approaches addressing the broader psychosocial contexts faced by pregnant individuals with pain.

Subject of Research: People

Article Title: Prescribed opioid analgesic use in pregnancy and risk of neurodevelopmental disorders in children: A retrospective study in Sweden

News Publication Date: September 16, 2025

Web References: http://dx.doi.org/10.1371/journal.pmed.1004721

References: Cleary EN, Sujan AC, Rickert ME, Fischer F, Lagerberg T, Chang Z, et al. (2025) Prescribed opioid analgesic use in pregnancy and risk of neurodevelopmental disorders in children: A retrospective study in Sweden. PLoS Med 22(9): e1004721. https://doi.org/10.1371/journal.pmed.1004721

Image Credits: cottonbro studio, Pexels (CC0)

Keywords: prenatal opioid exposure, autism spectrum disorder, attention-deficit/hyperactivity disorder, neurodevelopmental disorders, pregnancy, opioid analgesics, epidemiology, cohort study, confounding factors